Amended Statement of Beneficial Ownership (sc 13d/a)
June 21 2021 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of
1934
(Amendment No. 3)*
Aptevo
Therapeutics Inc.
|
(Name of Issuer)
|
|
Common Stock, par value $0.001
|
(Title of Class of Securities)
|
|
03835L207
|
(CUSIP Number)
|
Kevin Tang
Tang Capital Management, LLC
4747 Executive Drive, Suite 210
San Diego, CA 92121
(858) 200-3830
|
(Name, Address and Telephone Number of Person Authorized to
|
Receive Notices and Communications)
|
|
June 21,
2021
|
(Date of Event which Requires Filing of this Statement)
|
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule
because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note: Schedules filed in paper
format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for
other parties to whom copies are to be sent.
* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act
of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
(Continued on following pages)
CUSIP NO. 03835L207
|
13D
|
Page 2 of 6
|
1.
|
Names
of Reporting Persons.
I.R.S. Identification Nos. of
above persons (entities only).
Tang Capital Partners, LP
|
2.
|
Check
the Appropriate Box if a Member of a Group
(a) ¨
(b) ý
|
3.
|
SEC
Use Only
|
4.
|
Source
of Funds
WC
|
5.
|
Check
If Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)
o
|
6.
|
Citizenship
or Place of Organization
Delaware
|
Number
of
Shares Beneficially
Owned by
Each Reporting
Person With
|
7.
|
Sole
Voting Power
0
|
8.
|
Shared
Voting Power
1,760,000
|
9.
|
Sole
Dispositive Power
0
|
10.
|
Shared
Dispositive Power
1,760,000
|
11.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
1,760,000
|
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares ¨
|
13.
|
Percent
of Class Represented by Amount in Row (11)
39.6%
|
14
|
Type of Reporting
Person
PN
|
|
|
|
|
CUSIP NO. 03835L207
|
13D
|
Page 3 of 6
|
1.
|
Names
of Reporting Persons.
I.R.S. Identification Nos. of
above persons (entities only).
Tang Capital Management, LLC
|
2.
|
Check
the Appropriate Box if a Member of a Group
(a) ¨
(b) ý
|
3.
|
SEC
Use Only
|
4.
|
Source
of Funds
WC
|
5.
|
Check
If Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)
o
|
6.
|
Citizenship
or Place of Organization
Delaware
|
Number
of
Shares Beneficially
Owned by
Each Reporting
Person With
|
7.
|
Sole
Voting Power
0
|
8.
|
Shared
Voting Power
1,760,000
|
9.
|
Sole
Dispositive Power
0
|
10.
|
Shared
Dispositive Power
1,760,000
|
11.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
1,760,000
|
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares ¨
|
13.
|
Percent
of Class Represented by Amount in Row (11)
39.6%
|
14
|
Type of Reporting
Person
OO
|
|
|
|
|
CUSIP NO. 03835L207
|
13D
|
Page 4 of 6
|
1.
|
Names
of Reporting Persons.
I.R.S. Identification Nos. of
above persons (entities only).
Kevin Tang
|
2.
|
Check
the Appropriate Box if a Member of a Group
(a) ¨
(b) ý
|
3.
|
SEC
Use Only
|
4.
|
Source
of Funds
PF, WC, OO
|
5.
|
Check
If Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)
o
|
6.
|
Citizenship
or Place of Organization
United States
|
Number
of
Shares Beneficially
Owned by
Each Reporting
Person With
|
7.
|
Sole Voting
Power
0
|
8.
|
Shared
Voting Power
1,760,000
|
9.
|
Sole Dispositive
Power
0
|
10.
|
Shared
Dispositive Power
1,760,000
|
11.
|
Aggregate
Amount Beneficially Owned by Each Reporting Person
1,760,000
|
12.
|
Check
if the Aggregate Amount in Row (11) Excludes Certain Shares ¨
|
13.
|
Percent
of Class Represented by Amount in Row (11)
39.6%
|
14
|
Type of Reporting
Person
IN
|
|
|
|
|
Explanatory Note
This Statement on Schedule 13D (the “Statement”
or “Schedule 13D”) relates to the common stock, par value $0.001 (the “Common Stock”), of Aptevo Therapeutics
Inc., a Delaware corporation (the “Issuer”) and amends the Schedule 13D filed on November 6, 2020 (the “Original Schedule
13D”), as amended on November 18, 2020 and February 9, 2021 (together with the Original Schedule 13D, the “Schedule 13D”).
Capitalized terms used and not defined in this Amendment No. 3 have the meanings set forth in the Schedule 13D.
This Amendment No. 3 is being filed to amend
Item 4 and Item 7 of the Schedule 13D as set forth below. The percentages of beneficial ownership reported herein are based on 4,449,535
shares of Common Stock reported to be issued and outstanding as of May 10, 2021, as set forth in the Issuer’s Quarterly Report
on Form 10-Q that was filed with the Securities and Exchange Commission on May 11, 2021.
Item 4. Purpose of Transaction
Item 4 of the Schedule 13D is amended by adding
the following:
As previously disclosed: (i) on November 18,
2020, the Reporting Persons submitted a bid letter to the Board of Directors of the Issuer offering to acquire the remaining common stock
of the Issuer that Tang Capital Partners, LP did not already own for a price of $50.00 per share in cash (the “Bid Proposal”),
and (ii) on February 9, 2021, the Reporting Persons submitted two director nominees and an advisory proposal (the “Advisory Proposal”)
for consideration at the Issuer’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”).
On June 21, 2021, the Reporting Persons delivered
a letter to the Issuer withdrawing the nomination of Thomas Wei and Kevin Tang as directors for election at the Annual Meeting and withdrawing
the Bid Proposal due to the Issuer’s refusal to enter into a confidentiality agreement without a standstill provision. No action
was taken with respect to the Advisory Proposal. A copy of the June 21, 2021 letter is attached as Exhibit 4 and is incorporated by reference
in this Item 4 in its entirety.
Item 7. Material to Be Filed as Exhibits
|
Exhibit 1:
|
Joint Filing Agreement (previously filed)
|
|
Exhibit 2:
|
Bid letter, dated November 18, 2020 (previously filed)
|
|
Exhibit 3:
|
Notice of Stockholder Proposals, dated February 9, 2021 (previously filed)
|
|
Exhibit 4:
|
Letter, dated June 21, 2021
|
SIGNATURES
After reasonable inquiry
and to the best of his or its knowledge and belief, each of the following Reporting Persons certifies that the information set
forth in this statement is true, complete and correct.
June 21, 2021
|
Tang Capital Partners, LP
|
|
|
|
|
|
|
|
|
|
|
By:
|
Tang Capital Management, LLC
|
|
|
|
|
|
|
By:
|
/s/ Kevin Tang
|
|
|
|
Kevin Tang, Manager
|
|
|
Tang Capital Management, LLC
|
|
|
|
|
|
|
By:
|
/s/ Kevin Tang
|
|
|
|
Kevin Tang, Manager
|
|
|
/s/ Kevin Tang
|
|
|
Kevin Tang
|
|
EXHIBIT 4
TANG CAPITAL PARTNERS, LP
4747 EXECUTIVE DRIVE, SUITE 210, SAN
DIEGO, CA 92121
(858) 200-3830 FAX (858) 200-3837
By email and Federal Express
June 21, 2021
Board of Directors
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, Washington 98121
Dear Members of the Board:
We very much appreciate your decision to add to Aptevo’s
proxy statement Tang Capital Partners’ advisory proposal seeking shareholder approval to commence a process to sell Aptevo to the
highest bidder. In light of this decision, we hereby withdraw our nomination of Thomas Wei and myself as directors for election at the
2021 annual meeting. Additionally, since the Company is unwilling to enter into a confidentiality agreement without a standstill provision,
we hereby withdraw our acquisition proposal. Should the Company be willing to enter into a confidentiality agreement without a standstill
provision, we would be happy to consider a new acquisition proposal.
|
Sincerely,
|
|
|
|
|
Tang Capital Partners, LP
|
|
By: Tang Capital Management, LLC
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Kevin Tang
|
|
Name: Kevin Tang
|
|
Title: President
|
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Jul 2023 to Jul 2024